

# SGLT2 Inhibitors Market is Projected to Reach US\$ 32.75 Billion by 2034, Registering a CAGR of 6.9%

*The worldwide escalation in type 2 diabetes is driving the market demand.*

NEW YORK CITY, NY, UNITED STATES, December 2, 2024 /EINPresswire.com/ -- Our [SGLT2 inhibitors market](#) report has been prepared using advanced methodologies and research techniques to help businesses make strategic business decisions.

The most recent research study by Polaris Market Research reveals that the SGLT2 inhibitors market is anticipated to flourish at a stable rate. With a projected CAGR of 6.9%, the market was valued at USD 16.79 billion in 2024. It is ready to grow to USD 32.75 billion by 2034.



SGLT2 Inhibitors Market

□□□□□□ □□□□□□□□□□□□□□:

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a category of oral prescription medicines that are FDA-consented for usage with diet and exercise to lessen blood sugar in grown-ups with type 2 diabetes. Some SGLT2 inhibitors are also FDA-consented for usage in people with chronic kidney disease (CKD) or heart failure to lessen the probability of heart attack, stroke, or heart failure involving people who are diabetes-free.

□□□□□□□□ □□□□ □□□□□□ □□□ □□□□ □□ □□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/sgl2-inhibitors-market/request-for-sample?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/sgl2-inhibitors-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

One kind of SGLT2 inhibitor is now FDA consented to assist in enhancing blood sugar regulation in children 10 years or above with type 2 diabetes. Research is in progress to observe if SGLT2 inhibitors are of assistance in some kidney illnesses in children who do not have diabetes. The growing consciousness of improved diagnostic methods has caused a superior aggregate of



SGLT2 inhibitors operate by decreasing renal entrance for glucose, causing elevated urinary glucose elimination.”

*Polaris Market Research*

diabetes diagnoses, pushing the SGLT2 inhibitors market demand.

Key players in the SGLT2 inhibitors market include:

- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.

- Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Sanofi
- TheracosBio, LLC

Key players in the SGLT2 inhibitors market include:

Clinical Guidelines and Recommendations: The clinical directives and advice of spearheading health firms such as the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) continuously reinforce the usage of SGLT2 inhibitors for particular patient categories. This approval has created the surge of SGLT2 inhibitors boosting the demand for SGLT2 inhibitors market growth.

Growing Geriatric Population: The growing geriatric population globally is causing the surging occurrence of diabetes and connected health conditions. Because of age-connected elements, elderly people are at an elevated probability of advancing type 2 diabetes, causing a profound requirement for SGLT2 inhibitors.

Surge in New Drug Approvals: The augmentation of the market is impacted by the consent of contemporary drugs and enlarged symptoms by administrative organizations such as the FDA and EMA. SGLT2 inhibitors, acknowledged for their medicinal applications, have acquired growing consent for additional symptoms involving type 2 diabetes, heart failure, and chronic kidney disease.

Key players in the SGLT2 inhibitors market include:

[https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/request-for-discount-pricing?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

Key players in the SGLT2 inhibitors market include:

- The SGLT2 inhibitors market segmentation is based on indication, drug, distribution channel, and region.

- By indication analysis, the type 2 diabetes segment held the largest market share. This is due to the increasing existence of obesity emanating from substandard dietary options, indolent lifestyles, and elevated calorie food consumption. Contemporary lifestyles normally include extended periods of physical idleness pushed by desk-bound work, escalated screen times, and decreased physical strain.
- By distribution channel analysis, the online pharmacies segment is poised to register a significant CAGR. This is due to them offering exceptional ease to patients particularly those in distant and underserved areas. This augmented penetration has caused a growing market reach of SGLT2 inhibitors, rendering them more broadly obtainable.

□□□□□□□□ □□□□□□□□:

The research report covers all the major regions and sub-regions of the SGLT2 inhibitors market. The study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America accounted for the largest market share. This is primarily because of growing detrimental strain and inadequate mental health. Further, the growing existence of diabetes patients in North America has caused elevated demand for SGLT2 inhibitors in the region.

Asia Pacific: Asia Pacific is anticipated to witness the fastest CAGR from 2024 to 2032. The region's growing aging population, causing an elevated existence of type 2 diabetes among older grownups, fuels the regional market expansion.

□□□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□□□□□□□:

[https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/inquire-before-buying?utm\\_source=EIN&utm\\_medium=EIN&utm\\_campaign=EIN&utm\\_id=01](https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

□□□□:

How much is the SGLT2 inhibitors market?

The market size was valued at USD 16.79 billion in 2024 and is expected to reach USD 32.75 billion by 2034.

What is the growth rate of the SGLT2 inhibitors market?

The global market is projected to register a CAGR of 6.9% during the forecast period 2025-2034.

Which region held the largest market share?

North America had the largest share of the global market in 2024.

Which indication led the market in 2024?

The type 2 diabetes category dominated the market in 2024.

Polymers' market is expected to grow at a CAGR of 6.9% in the forecast period (2025-2034)

[SGLT2 Inhibitors Industry](https://www.polarismarketresearch.com/industry-analysis/sgl2-inhibitors-industry) is growing at a CAGR of 6.9% in the forecast period (2025-2034)

Metastatic Lung Adenocarcinoma Treatment Market:

Metastatic Lung Adenocarcinoma Treatment Market:

<https://www.polarismarketresearch.com/industry-analysis/metastatic-lung-adenocarcinoma-treatment-market>

Medical Batteries Market:

<https://www.polarismarketresearch.com/industry-analysis/medical-batteries-market>

In Vitro Diagnostics Market:

<https://www.polarismarketresearch.com/industry-analysis/in-vitro-diagnostics-market>

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market:

<https://www.polarismarketresearch.com/industry-analysis/blastic-plasmacytoid-dendritic-cell-neoplasm-market>

DNA Diagnostics Market:

<https://www.polarismarketresearch.com/industry-analysis/dna-diagnostics-market>

US Organoids and Spheroids Market:

<https://www.polarismarketresearch.com/industry-analysis/us-organoids-and-spheroids-market>

Polymers market is expected to grow at a CAGR of 6.9% in the forecast period (2025-2034)

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+1 929-297-9727

[sales@polarismarketresearch.com](mailto:sales@polarismarketresearch.com)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/765451861>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.